POZEN Inc

POZEN — Merger or Acquisition (August 2015)

27 slides from POZEN's merger presentation, Aug 10, 2015

  1. Slide 1: Strategic Rationale and Vision for Aralez Pharmaceuticals

    “Strategic Rationale and Vision for Aralez Pharmaceuticals” August, 2015

  2. Slide 2: Forward-looking statements

    This presentation contains forward-looking statements under applicable securities laws, including, but not limited to, statements related to the anticipated consummation of the business combination transaction among Aralez, POZEN and Tribute and the timing and benefits thereof, the anticipated equit

  3. Slide 3: A Transformational Combination

    A Transformational Combination World-Class Management with History of Success Diversified, Growing Revenue Base with North American Focus Strong Balance Sheet & Financial Position Irish Domicile Offers Financial & Competitive Advantage $150M at close ($75m equity/$75m convertible note) $200M committ

  4. Slide 4: Aralez: Creating a Platform for Growth

    Aralez: Creating a Platform for Growth Strong Balance Sheet Platform for Growth Diversified Revenue Streams and Portfolio Adrian Adams (CEO) and Andrew Koven (President & CBO) have track record of value creation Auxilium (Endo), Inspire (Merck), Sepracor (Dainippon Sumitomo) and Kos (Abbott) World C

  5. Slide 5: Transaction Overview

    Transaction Overview Structure POZEN and Tribute will each become wholly owned subsidiaries of Aralez Aralez will be an Irish plc Aralez shares are expected to trade on Nasdaq and the TSX upon closing Exchange Ratio POZEN: 1.000 share of Aralez for each share of POZEN Tribute: 0.1455 share of Aralez

  6. Slide 6: POZEN

    POZEN Transforming medicine. Transforming lives.

  7. Slide 7: YOSPRALA - Provides Coordinated Delivery of Aspirin and Omeprazole

    YOSPRALA - Provides Coordinated Delivery of Aspirin and Omeprazole ‘Coordinated’ delivery means Immediate release of omeprazole to establish optimal pH followed by: Release of aspirin when pH reaches optimum level Efficacy / Tolerability profile supported by full Phase 3 program Significant reductio

  8. Slide 8: YOSPRALA: Significant Commercial Opportunity

    YOSPRALA: Significant Commercial Opportunity YOSPRALA is a unique formulation of delayed-release aspirin and immediate-release omeprazole for the secondary prevention of heart attack and stroke Market Opportunity 24 MM* secondary prevention patients in US 70% take aspirin** Over 40% of physicians pr

  9. Slide 9: YOSPRALA Update

    YOSPRALA API Aspirin Manufacturer Status YOSPRALA API primary aspirin manufacturer executing against its action plan to address FDA issues: will be subject to FDA re-inspection Steps also being taken to qualify a second supplier of aspirin API Prelaunch Preparations Scaling up and building out comme

  10. Slide 10: YOSPRALA: Regulatory Status

    US: PA32540/PA8140 NDA filing 505b(2) application Proposed label for secondary prevention of CVD per aspirin monograph (excluding acute MI) API aspirin manufacturer appears on track with corrective actions that FDA has deemed acceptable pending verification Continuing to pursue alternate supplier fo

  11. Slide 11: YOSPRALA and MT400: Canadian Opportunity

    YOSPRALA and MT400: Canadian Opportunity Opportunity Selected Market Research Timing Tracking Heart Disease & Stroke in Canada – June 2009; 4.8% Heart Disease ;1.1% Stroke (Public Health Agency of Canada; www.publichealth.gc.ca ** Praxis Yosprala Acceptance Study, April 2015, 403 physicians and 494

  12. Slide 12: YOSPRALA: Protected by a Robust Patent Position

    ‘A pharmaceutical composition in unit dosage form comprising an enteric-coated NSAID and a non-enteric-coated acid inhibitor formulated for coordinated release’ CA 2 449 098 C (expires 5/31/2022) Counterpart upheld by EPO Opposition Division 12/12/2012 Also issued: Australia, Eurasia, Israel, Japan,

  13. Slide 13: Tribute Pharmaceuticals

    TRIBUTE PHARMACEUTICALS

  14. Slide 14: Tribute: Compelling Canadian Growth Story

    Tribute: Compelling Canadian Growth Story Tribute is a Canadian specialty pharmaceutical company focused on the acquisition, licensing, development and promotion of Canadian and US healthcare products Sales force of 28 sales representatives across Canada 20 primary care (PCPs/GPs, neurologists, derm

  15. Slide 15: Fibricor

    Indications Severe Hypertriglyceridemia Primary Hypercholesterolemia or Mixed Dyslipidemia Unique fenofibric acid formulation competes in the US$2.5 billion triglyceride lowering medication market Protected by 4 separate patents valid until August 20, 2027 Product sales of approximately US$4.7 milli

  16. Slide 16: Bezalip SR and Soriatane

    Bezalip SR Bezalip SR & Soriatane Historical Sales *Source: IMS Combined historical sales for Bezalip SR & Soriatane Well established with 25 years of therapeutic use globally and approved more than 40 countries Modified-release tablet that contains the active ingredient bezafibrate Once-a-day dosin

  17. Slide 17: CAMBIA

    CAMBIA *Lipton RB, et al – Headache. 1998.38.87.96. Only prescription NSAID available and approved for the acute treatment of migraine attached with or without aura in adults 18 years of age or older New patented, water soluble, buffered powder formulation designed to deliver a 50mg dose when mixed

  18. Slide 18: Tribute - Acquisition of Medical Futures Inc.

    Tribute - Acquisition of Medical Futures Inc. *Includes about $1.8 million in Florastor sales: Contract Terminated in 2014. * Revenue CDN$ 13 marketed products and 2 pipeline products Total purchase price + Cdn$25 million $6 million cash contingent milestones (anticipated within 90 days) Cdn$1.25 mi

  19. Slide 19: Aralez – Strong Projected Revenue Growth

    Aralez – Strong Projected Revenue Growth* $75M equity Robust balance sheet and demonstrated access to capital $75M convertible debt 2.5% with 32.5% premium $200M credit facility For future acquisitions * Figures reflect the addition of standalone projections and do not include any synergies or chang

  20. Slide 20: The Aralez Growth Strategy & Priorities

    The Aralez Growth Strategy & Priorities Maximize the value of expanded portfolio & geographic footprint Build around a cardiovascular-based, North American-focused portfolio Aggressive approach to CD&L and M&A to drive growth supported by new platform Leverage platform for growth with tax-efficient

  21. Slide 21: Our Near Term Priorities

    Advance YOSPRALA to submission and approval Focus on YOSPRALA prelaunch preparations & execute commercialization strategy Successfully close the Tribute Pharmaceuticals merger in the 4Q15 Finalize S-4 and go effective Clear HSR notification waiting period Prepare for special shareholder meeting Work

  22. Slide 22: Strategic Rationale and Vision for Aralez Pharmaceuticals

    “Strategic Rationale and Vision for Aralez Pharmaceuticals” July, 2015

  23. Slide 23: World Class Management Team with Proven Track Record

    World Class Management Team with Proven Track Record of Successfully Growing Companies Kos Pharmaceuticals: Licensed NIASPAN and ADVICOR to Oryx in Canada Licensed NIASPAN and ADVICOR to Merck KGa in Europe Co-Promotion with Takeda for NIASPAN in US Co-Promotion with Barr Laboratories for NIASPAN in

  24. Slide 24: YOSPRALA Reduces Gastric Damage vs. EC Aspirin in Proof-of-Concept Trials

    YOSPRALA Consistently and Significantly Reduces Gastric Damage vs. EC Aspirin in Proof-of-Concept Trials Lanza Grading 0 = no visible lesions; 1 = 1 lesion; 2 = 2-10 lesions; 3 = 11-25 lesions; 4 = >25 lesions or an ulcer Methods Pooled results of POZEN studies (PA32520-101, -102, and -106) plus PA8

  25. Slide 25: Significant Reduction of Gastric Ulcers with PA32540 at 6 Months

    Significant Reduction of Gastric Ulcers, Gastro-duodenal Ulcers and Discontinuations with PA32540 at 6 Months PA32540-301 and PA32540-302 ITT Population; PA32540 (n=524), EC ASA (n=525) P < 0.001 P < 0.001 Percentage of Subjects 63% 71% P < 0.001 82%

  26. Slide 26: Complementary Products & Pipeline

    Cardiovascular Pain Other Specialty Products Complementary Products & Pipeline MT400 Subject to approval in referenced market. Bezalip SR is approved in Canada but not approved in the United States. Treximet and VIMOVO are marketed by commercial partners of POZEN. VIMOVO is marketed outside of North

  27. Slide 27: Medical Futures Inc. Products

    Medical Futures Inc. Products

Pozen — Merger or Acquisition (August 2015) on 6ix